ReNeuron Group — Encouraging data for iPSCs opens potential

ReNeuron Group (AIM: RENE)

Last close As at 20/11/2024

3.38

0.00 (0.00%)

Market capitalisation

2m

More on this equity

ReNeuron Group — Encouraging data for iPSCs opens potential

ReNeuron Group has presented encouraging preclinical data surrounding the company’s conditionally immortalised induced pluripotent stem cell (CI iPSC) line. The results show that, using the group’s proprietary conditional immortalisation technology, ReNeuron can achieve enhanced control of growth and survival of CI-iPSC-derived cells, including Schwann cells, providing a potentially key differentiator over traditional iPSCs. While we acknowledge that these are early stage results, the latest data may also bode well for the group’s customisable exosome platform (CustomEx) and could further enhance the current exosome offering into new indications and targets. We continue to value ReNeuron at £44.2m or 77p per share.

Analyst avatar placeholder

Written by

ReNeuron Group

Encouraging data for iPSCs opens potential

Preclinical data update

Pharma and biotech

9 December 2022

Price

11.75p

Market cap

£7m

US$1.23/£

Gross cash (£m) at 30 September 2022

10.5

Shares in issue

57.1m

Free float

99.7%

Code

RENE

Primary exchange

LSE

Secondary exchange

N/A

Share price performance

Business description

ReNeuron Group is a UK biotech focused on the development of its stem cell-derived exosome drug delivery platform (CustomEx). The company operates as a contract research and development organisation and has established partners that are progressing the preclinical development of exosome-based therapeutics, utilising ReNeuron’s CustomEx technology.

Analysts

Soo Romanoff

+44 (0)20 3077 5700

Dr Adam McCarter

+44 (0)20 3077 5700

ReNeuron Group is a research client of Edison Investment Research Limited

ReNeuron Group has presented encouraging preclinical data surrounding the company’s conditionally immortalised induced pluripotent stem cell (CIiPSC) line. The results show that, using the group’s proprietary conditional immortalisation technology, ReNeuron can achieve enhanced control of growth and survival of CI-iPSC-derived cells, including Schwann cells, providing a potentially key differentiator over traditional iPSCs. While we acknowledge that these are early stage results, the latest data may also bode well for the group’s customisable exosome platform (CustomEx) and could further enhance the current exosome offering into new indications and targets. We continue to value ReNeuron at £44.2m or 77p per share.

Year end

Revenue
(£m)

PBT*

(£m)

EPS*
(£)

DPS
(£)

P/E
(x)

Yield
(%)

03/21

0.3

(13.4)

(0.29)

0.0

N/A

N/A

03/22

0.4

(11.1)

(0.17)

0.0

N/A

N/A

03/23e

0.8

(8.9)

(0.13)

0.0

N/A

N/A

03/24e

0.9

(9.6)

(0.14)

0.0

N/A

N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

IPSCs are adult stems cells that have been reprogrammed back into an embryonic-like state, potentially allowing for the development of any type of human cell needed for therapeutic purposes. ReNeuron’s CI-iPSC cell-line technology is currently being developed as a platform in collaboration with University College London. Investigations so far focused on the production of Schwann cells for peripheral nerve damage repair and in the generation of CAR-T and CAR-NK cells for anti-cancer treatment as ‘off-the-shelf’ therapies.

Existing patient-derived (autologous) cell therapies have drawbacks that include patients’ cells potentially being disease compromised, and costly, time-consuming manufacturing. To address these issues, there is an increasing trend within the cell therapy market to move towards ‘off-the-shelf’ products, so we see the latest development of ReNeuron’s iPSC technology as a positive step towards realising such ‘off-the-shelf’ potential .

Additionally, the CI-iPSC platform provides an opportunity to generate any stem cell type and, ultimately, any type of tissue-specific exosome. The enhancement of the CustomEx drug delivery platform forms a critical part of ReNeuron’s new strategy, so we see the iPSC development as highly encouraging.

General disclaimer and copyright

This report has been commissioned by ReNeuron Group and prepared and issued by Edison, in consideration of a fee payable by ReNeuron Group. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2022 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on ReNeuron Group

View All

Research: Financials

Molten Ventures — High emphasis on capital preservation

Molten Ventures reported a c 11% decline in NAV per share to 837p in H123 versus FY22, broadly in line with its trading update in early November. Its gross portfolio value was down 17% in constant currency, partially offset by a 5% positive foreign exchange impact from a stronger US dollar. While the enterprise values (EVs) of its portfolio holdings were marked down on average by c 35% (primarily in response to the softening valuations across public equities year-to-date), we note that the portfolio was more resilient than the broader IT market on the back of exposure to disruptive tech, including enterprise software. On top of that, the impact on Molten’s NAV was partially offset by 90% of its investments being structured as preference shares. The company invested £112m in H123 but plans a slower pace in H223 and targets £150m for FY23.

Continue Reading
molten03

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free